Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.70 |
| ▸ | TK2 | O00142 | 2/20 | 0.65 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.54 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MTOR | P42345 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6671812 | 1.00 | PYGM (0.70) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL1138789 | 1.00 | PYGM (0.70) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Phosphoric Acid SCHEMBL6519313 | 0.95 | PYGM (0.65) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2583461 | 0.88 | PYGM (0.56) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL15011448 | 0.87 | P2RY2 (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL28975480 | 0.87 | P2RY2 (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL28975481 | 0.87 | PYGM (0.57) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2056641 | 0.85 | PYGM (0.72) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL14928850 | 0.85 | PYGM (0.72) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2056643 | 0.85 | PYGM (0.72) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20260049338-A1 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | FACTOR BIOSCIENCE INC (US) | 2026-02-19 | — | — | US | claimed |
| US-12384740-B2 | Cationic lipids and transfection methods | FACTOR BIOSCIENCE INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-12357664-B2 | Optimized oncolytic viruses and uses thereof | SATOR THERAPEUTICS (US) | 2025-07-15 | — | — | US | claimed |
| CN-114450265-B | Cationic lipids and uses thereof | 菲克特生物科学股份有限公司 | 2024-12-24 | — | — | CN | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| US-20230373903-A1 | CATIONIC LIPIDS AND TRANSFECTION METHODS | FACTOR BIOSCIENCE INC. | 2023-11-23 | — | — | US | claimed |
| US-11814333-B2 | Cationic lipids and transfection methods | FACTOR BIOSCIENCE INC. (US) | 2023-11-14 | — | — | US | claimed |
| US-20230323399-A1 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | FACTOR BIOSCIENCE INC. | 2023-10-12 | — | — | US | claimed |
| US-20230304044-A1 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | FACTOR BIOSCIENCE INC. | 2023-09-28 | — | — | US | claimed |
| US-20020004590-A1 | Method for producing nucleoside-5'-phosphate ester | MIHARA YASUHIRO (JP) | 2002-01-10 | — | — | US | claimed |
| US-6207435-B1 | MUTANT ACID PHOSPHATASE HAVING DECREASED MICHAELIS CONSTANT FOR A NUCLEOSIDE AND/OR INCREASED TEMPERATURE STABILITY; FOR EFFICIENT PHOSPHORYLATION OF NUCLEOSIDES TO PRODUCE NUCLEOTIDES | AJINOMOTO CO., INC. (JP) | 2001-03-27 | — | — | US | claimed |
| EP-0661291-B1 | Solid phase synthesis of oligoribonucleotide | AVENTIS PHARMA GMBH (DE) | 2001-03-07 | — | — | EP | claimed |
| US-6063628-A | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2000-05-16 | — | — | US | claimed |
| US-6015697-A | ECONOMICAL AND EFFICIENT PROCESS BY REACTING A NUCLEOSIDE WITH A PHOSPHATE DONOR GROUP IN PRESENCE OF MUTANT ACID PHOSPHATASE WITH DECREASED MICHAELIS CONSTANT FOR NUCLEOSIDE OR INCREASED TEMPERATURE STABILITY | AJINOMOTO CO., INC. (JP) | 2000-01-18 | — | — | US | claimed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | claimed |
| US-5652358-A | Solid-phase synthesis of oligoribonucleotides | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-07-29 | — | — | US | claimed |
| EP-0661291-A1 | Solid phase synthesis of oligoribonucleotide | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-07-05 | — | — | EP | claimed |
| EP-0653439-A2 | Stabilized oligonucleotids and the use thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-05-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | PYGM 4730/4885TK2 696/4885SLC28A1 74/4885 |
| US-20230323399-A1 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | NSUN3, STING1, NFATC1 | PYGM 2631/4885TK2 309/4885SLC28A1 784/4885 |
| US-20230373903-A1 | CATIONIC LIPIDS AND TRANSFECTION METHODS | CETP, NPC1L1, NPC1 | PYGM 4509/4885TK2 671/4885SLC28A1 321/4885 |
| US-12384740-B2 | Cationic lipids and transfection methods | CETP, NPC1L1, NPC1 | PYGM 4509/4885TK2 671/4885SLC28A1 321/4885 |
| US-20230304044-A1 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | NSUN3, STING1, NFATC1 | PYGM 2631/4885TK2 309/4885SLC28A1 784/4885 |
| US-11814333-B2 | Cationic lipids and transfection methods | CETP, NPC1L1, NPC1 | PYGM 4509/4885TK2 671/4885SLC28A1 321/4885 |
| US-20260049338-A1 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | NSUN2, RNGTT, RNMT | PYGM 3223/4885TK2 454/4885SLC28A1 228/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | PYGM 3199/4885TK2 59/4885SLC28A1 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.